Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

DURECT Corporation

DRRXNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$1.91
$-0.02(-1.04%)
U.S. Market opens in 15h 27m

DURECT Corporation Fundamental Analysis

DURECT Corporation (DRRX) shows weak financial fundamentals with a PE ratio of -17.05, profit margin of -1.10%, and ROE of -70.85%. The company generates $0.0B in annual revenue with weak year-over-year growth of -76.24%.

Key Strengths

Cash Position10.97%
PEG Ratio-0.51

Areas of Concern

ROE-70.85%
Operating Margin-5.32%
Current Ratio0.98
We analyze DRRX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -210.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-210.1/100

We analyze DRRX's fundamental strength across five key dimensions:

Efficiency Score

Weak

DRRX struggles to generate sufficient returns from assets.

ROA > 10%
-27.86%

Valuation Score

Excellent

DRRX trades at attractive valuation levels.

PE < 25
-17.05
PEG Ratio < 2
-0.51

Growth Score

Moderate

DRRX shows steady but slowing expansion.

Revenue Growth > 5%
-76.24%
EPS Growth > 10%
77.87%

Financial Health Score

Moderate

DRRX shows balanced financial health with some risks.

Debt/Equity < 1
0.44
Current Ratio > 1
0.98

Profitability Score

Weak

DRRX struggles to sustain strong margins.

ROE > 15%
-7084.95%
Net Margin ≥ 15%
-1.10%
Positive Free Cash Flow
No

Key Financial Metrics

Is DRRX Expensive or Cheap?

P/E Ratio

DRRX trades at -17.05 times earnings. This suggests potential undervaluation.

-17.05

PEG Ratio

When adjusting for growth, DRRX's PEG of -0.51 indicates potential undervaluation.

-0.51

Price to Book

The market values DURECT Corporation at 15.06 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

15.06

EV/EBITDA

Enterprise value stands at -4.32 times EBITDA. This is generally considered low.

-4.32

How Well Does DRRX Make Money?

Net Profit Margin

For every $100 in sales, DURECT Corporation keeps $-1.10 as profit after all expenses.

-1.10%

Operating Margin

Core operations generate -5.32 in profit for every $100 in revenue, before interest and taxes.

-5.32%

ROE

Management delivers $-70.85 in profit for every $100 of shareholder equity.

-70.85%

ROA

DURECT Corporation generates $-27.86 in profit for every $100 in assets, demonstrating efficient asset deployment.

-27.86%

Following the Money - Real Cash Generation

Operating Cash Flow

DURECT Corporation generates limited operating cash flow of $-13.96M, signaling weaker underlying cash strength.

$-13.96M

Free Cash Flow

DURECT Corporation generates weak or negative free cash flow of $-13.97M, restricting financial flexibility.

$-13.97M

FCF Per Share

Each share generates $-0.45 in free cash annually.

$-0.45

FCF Yield

DRRX converts -23.55% of its market value into free cash.

-23.55%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-17.05

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.51

vs 25 benchmark

P/B Ratio

Price to book value ratio

15.06

vs 25 benchmark

P/S Ratio

Price to sales ratio

18.84

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.44

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.98

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.71

vs 25 benchmark

ROA

Return on assets percentage

-0.28

vs 25 benchmark

ROCE

Return on capital employed

-3.65

vs 25 benchmark

How DRRX Stacks Against Its Sector Peers

MetricDRRX ValueSector AveragePerformance
P/E Ratio-17.0529.28 Better (Cheaper)
ROE-70.85%820.00% Weak
Net Margin-110.48%-19743.00% (disorted) Weak
Debt/Equity0.440.26 Weak (High Leverage)
Current Ratio0.984.69 Weak Liquidity
ROA-27.86%-17807.00% (disorted) Weak

DRRX outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews DURECT Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-96.05%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

76.72%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

-198.94%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ